RESUMO
In recent years, the Japanese Teratology Society has worked with the DevTox Berlin Workshops project to provide internationally consistent terminology for teratogenic effects. This paper summarizes a satellite workshop of the 60th Annual Meeting of the Japanese Teratology Society, which was entitled "Current activities between DevTox Berlin Workshops to develop a harmonized terminology for classifying anomalies in laboratory animals in developmental toxicity studies." The Japanese Teratology Society - Laboratory Animal Terminology Project (JTS-LATP) reviewed "gray zone" anomalies and focused on developing criteria for reclassifying a large number of gray zone anomalies to clarify them and to make it easier to judge fetal categories. This effort will lead to international agreement, based on shared conceptions. The present article aimed to provide the reader with a summary of the issues discussed at the 2020 satellite meeting, which included discussions on open issues from the DevTox Berlin Workshops, ongoing work by the JTS-LATP on gray zone (GZ) anomalies, current industrial concerns, and future challenges.
Assuntos
Anormalidades Induzidas por Medicamentos , Animais de Laboratório/anormalidades , Teratologia , Animais , Berlim , Feto/anormalidades , Feto/efeitos dos fármacos , JapãoRESUMO
The prenatal developmental toxicity of the fumes of oxidised asphalt (OA) was tested by nose-only inhalation in the rat. The test material was generated by collecting fumes from the headspace of storage tanks filled with OA. The composition of these fumes was matched to fumes sampled at a workplace where the same OA was applied in a pour-and-roll operation, representing occupational exposure with high concentrations of fumes to not underestimate the possible hazard. In the main study, dams were exposed to 0, 53, 158 and 536â¯mg/m3 of fume (as total organic mass), for 6â¯h/day for 19 days p.c. The maternal NOAEC was 53â¯mg/m³ (lowest dose tested). In the high-dose group treatment-related effects on body weight gain were seen. In the mid- and high-dose groups treatment-related effects on food consumption, lung weights, and histopathological changes in lungs and the upper respiratory tract were observed. The NOAEC for prenatal developmental toxicity was 536â¯mg/m³ since no exposure-related effects were found in any of the exposure groups for any of the investigated reproductive endpoints. Furthermore, nose-only exposure to OA fumes in concentrations up to 536â¯mg/m³ from days 1-19 p.c. did not induce any significant fetal abnormalities.
Assuntos
Hidrocarbonetos/toxicidade , Exposição por Inalação , Animais , Feminino , Pulmão , Masculino , Exposição Ocupacional , Gravidez , Ratos , ReproduçãoRESUMO
25 years after the first Berlin Workshop on Developmental Toxicity this 10th Berlin Workshop aimed to bring together international experts from authorities, academia and industry to consider scientific, methodologic and regulatory aspects in risk assessment of developmental toxicity and to debate alternative strategies in testing developmental effects in the future. Proposals for improvement of the categorization of developmental effects were discussed as well as the update of the DevTox database as valuable tool for harmonization. The development of adverse outcome pathways relevant to developmental neurotoxicity (DNT) was debated as a fundamental improvement to guide the screening and testing for DNT using alternatives to animal methods. A further focus was the implementation of an in vitro mechanism-based battery, which can support various regulatory applications associated with the assessment of chemicals and mixtures. More interdisciplinary and translation research should be initiated to accelerate the development of new technologies to test developmental toxicity. Technologies in the pipeline are (i) high throughput imaging techniques, (ii) models for DNT screening tests, (iii) use of computer tomography for assessment of thoracolumbar supernumerary ribs in animal models, and (iv) 3D biofabrication of bone development and regeneration tissue models. In addition, increased collaboration with the medical community was suggested to improve the relevance of test results to humans and identify more clinically relevant endpoints. Finally, the participants agreed that this conference facilitated better understanding innovative approaches that can be useful for the identification of developmental health risks due to exposure to chemical substances.
Assuntos
Desenvolvimento Ósseo/efeitos dos fármacos , Educação , Doenças do Sistema Nervoso/induzido quimicamente , Toxicologia/métodos , Aniversários e Eventos Especiais , Berlim , Uso da Internet , Sistema Nervoso/efeitos dos fármacos , Sistema Nervoso/crescimento & desenvolvimento , Medição de RiscoRESUMO
The prenatal developmental toxicity of bitumen fume was tested by nose-only inhalation in the rat. The fumes for exposure were collected from the headspace of a storage tank filled with a bitumen corresponding in composition to an anticipated worst-case occupational exposure. The composition of these fumes was compared to actual paving site fumes to ensure its representativeness for workplace exposures. In a dose-range-finding study male and female rats were exposed to 0, 103, 480 or 1043â¯mg/m3 of fume (as total organic mass), for 6â¯h/day during 20 days post conception (p.c.). Dose-related effects on body weight and lungs were observed in the mid- and high-dose groups. In the main study, dams were exposed to 0, 52, 151 and 482â¯mg/m3 of fume, for 6â¯h/day during 19 days p.c. The maternal NOAEL was 52â¯mg/m³. In the high-dose group treatment-related effects on body weight (gain), food consumption, lung weights, and histopathological changes in lungs and larynx were observed. In the mid-dose group only histopathological changes in the larynx and lungs were found. The NOAEL for prenatal developmental toxicity was 151â¯mg/m³ based on reduced fetal weight in the high-dose group (482â¯mg/m³). However, these changes are most likely a consequence of the maternal toxicity, in particular the reduction of maternal body weight gain by 26 % as compared to control. Nose-only exposure to bitumen fumes in concentrations up to 482â¯mg/m³ from days 1-19 p.c. did not induce any significant fetal anomalies.
Assuntos
Poluentes Ocupacionais do Ar/toxicidade , Hidrocarbonetos/toxicidade , Administração por Inalação , Aerossóis/análise , Aerossóis/toxicidade , Poluentes Ocupacionais do Ar/análise , Animais , Peso Corporal/efeitos dos fármacos , Monitoramento Ambiental , Feminino , Feto/efeitos dos fármacos , Humanos , Hidrocarbonetos/análise , Exposição por Inalação/análise , Laringe/efeitos dos fármacos , Laringe/patologia , Pulmão/efeitos dos fármacos , Pulmão/patologia , Masculino , Troca Materno-Fetal , Nível de Efeito Adverso não Observado , Exposição Ocupacional/análise , Gravidez , Ratos WistarRESUMO
Representatives of applied science (e.g. governmental organizations, academia, and industry) met to discuss the progress towards a harmonized human health risk assessment in developmental toxicology of plant protection products, biocidal products, and other environmental chemicals at the 9th Berlin Workshop on Developmental Toxicity held in September 2018. Within the focus of the scientific discussion were the future of in-vitro methods for developmental and reproductive toxicology, the potential relevance of alternative species in testing of developmental effects, and risk and hazard assessment of developmental and endocrine effects. Furthermore, the need for a harmonized terminology for classification of anomalies in laboratory animals in developmental toxicity studies aiming for human health risk assessment was determined. Here, the DevTox database was identified as an extremely valuable tool. Overall, the participants agreed that still one of the biggest challenges for testing developmental toxicity in the 21st century is the development of animal-free test strategies and alternatives to animal testing that could provide human-relevant information in a rapid, efficient, and mechanistically informative manner.
Assuntos
Alternativas ao Uso de Animais/métodos , Bases de Dados Factuais/tendências , Reprodução/efeitos dos fármacos , Toxicologia/métodos , Alternativas ao Uso de Animais/tendências , Animais , Berlim , Medição de Risco , Especificidade da Espécie , Terminologia como Assunto , Toxicologia/tendênciasRESUMO
This article is a report of the 8th Berlin Workshop on Developmental Toxicity held in May 2014. The main aim of the workshop was the continuing harmonization of terminology and innovations for methodologies used in the assessment of embryo- and fetotoxic findings. The following main topics were discussed: harmonized categorization of external, skeletal, visceral and materno-fetal findings into malformations, variations and grey zone anomalies, aspects of developmental anomalies in humans and laboratory animals, and innovations for new methodologies in developmental toxicology. The application of Version 2 terminology in the DevTox database was considered as a useful improvement in the categorization of developmental anomalies. Participants concluded that initiation of a project for comparative assessments of developmental anomalies in humans and laboratory animals could support regulatory risk assessment and university-based training. Improvement of new methodological approaches for alternatives to animal testing should be triggered for a better understanding of developmental outcomes.
Assuntos
Terminologia como Assunto , Toxicologia , Anormalidades Induzidas por Medicamentos , Animais , Humanos , Medição de Risco , Teratogênicos/toxicidade , Toxicologia/métodosRESUMO
As major immunological and hematological parameters evolve during the early period of life, laboratory data must be interpreted in relation to developmental changes. Wistar (WU) rats were sacrificed on PND2, 4, 7, 10, 14, 17 and 21. Peripheral blood, bone marrow, thymus samples and spleen cells were collected and a bronchoalveolar lavage (BAL) performed. Parameters of blood counts changed considerably between time points. IgM and IgG levels steadily increased. Spontaneous spleen cell proliferation was low before PND21, although mitogens had stimulatory effects above baseline. In the spleen, T-lymphocyte counts tripled by PND17 (mainly attributed to CD8(+) cytotoxic T-cells and CD4(+) T-helper cells). In peripheral blood an increase in B-lymphocytes to about 60% of the cell number was observed. In BAL fluid, macrophages represented 95-98% of the cells. In thymus architecture, lymphoblast migration was seen and epithelial structures appeared. The data presented will help to distinguish between maturational changes and treatment-related effects.
Assuntos
Sistema Hematopoético/crescimento & desenvolvimento , Sistema Imunitário/crescimento & desenvolvimento , Fatores Etários , Animais , Animais Recém-Nascidos , Subpopulações de Linfócitos B/imunologia , Subpopulações de Linfócitos B/metabolismo , Biomarcadores/sangue , Contagem de Células Sanguíneas , Líquido da Lavagem Broncoalveolar/imunologia , Proliferação de Células , Células Cultivadas , Sistema Hematopoético/metabolismo , Sistema Imunitário/imunologia , Sistema Imunitário/metabolismo , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Ativação Linfocitária , Ratos Wistar , Baço/imunologia , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo , Timo/crescimento & desenvolvimento , Timo/imunologia , Timo/metabolismoRESUMO
Poor maternal nutrition during gestation can lead to intrauterine growth retardation (IUGR), a main cause of low birth weight associated with high neonatal morbidity and mortality. Such early uterine environmental exposures can impact the neonatal epigenome to render later-in-life disease susceptibility. We established in Wistar Han rats a mild IUGR model induced by gestational protein deficiency (i.e. 9% crude protein in low protein diet vs. 21% in control, from GD 0 to 21) to identify alterations in gene expression and methylation patterns in certain genes implicated in human IUGR or in placental development. We found differential gene expression of Wnt2 and Dlk1 between IUGR and control. Notably, Wnt2 exhibited significant decrease while Dlk1 increase in IUGR placentas, correlating to decrease in fetal and placental weight. Methylation patterns encompassing 30 CpGs in the Wnt2 promoter region revealed variability in both IUGR and control placentas, but a site-specific hypomethylation was evident in IUGR placentas. Our present findings further support a key role of maternal gestational nutrition in defining the neonatal epigenome.
Assuntos
Metilação de DNA , Retardo do Crescimento Fetal/etiologia , Retardo do Crescimento Fetal/genética , Regulação da Expressão Gênica no Desenvolvimento , Placenta/metabolismo , Deficiência de Proteína/complicações , Animais , Modelos Animais de Doenças , Epigênese Genética , Feminino , Peptídeos e Proteínas de Sinalização Intercelular/genética , Masculino , Proteínas de Membrana/genética , Gravidez , Deficiência de Proteína/genética , Ratos Wistar , Proteína Wnt2/genéticaRESUMO
DNAzymes are single-stranded catalytic DNA molecules that bind and cleave specific sequences in a target mRNA molecule. Their potential as novel therapeutic agents has been demonstrated in a variety of disease models. However, no studies have yet addressed their toxicology and safety pharmacology profiles in detail. Here we describe a detailed toxicological analysis of inhaled hgd40, a GATA-3-specific DNAzyme designed for the treatment of allergic bronchial asthma. Subacute toxicity, immunotoxicity, and respiratory, cardiovascular, and CNS safety pharmacology were analyzed in rodents and non-rodents, and genotoxicity was assessed in human peripheral blood. Overall, hgd40 was very well tolerated when delivered by aerosol inhalation or slow intravenous infusion. Only marginal reversible histopathological changes were observed in the lungs of rats receiving the highest dose of inhaled hgd40. The changes consisted of slight mononuclear cell infiltration and alveolar histiocytosis, and moderate hyperplasia of bronchus-associated lymphoid tissue. No local or systemic adverse effects were observed in dogs. No compound-related respiratory, cardiovascular, or CNS adverse events were observed. The only relevant immunological findings were very slight dose-dependent changes in interleukin-10 and interferon-γ levels in bronchoalveolar lavage fluid. Taken together, these results support direct delivery of a DNAzyme via inhalation for the treatment of respiratory disease.
Assuntos
DNA Catalítico/toxicidade , Fator de Transcrição GATA3/genética , Administração por Inalação , Animais , Encéfalo/efeitos dos fármacos , Líquido da Lavagem Broncoalveolar/imunologia , DNA Catalítico/administração & dosagem , Cães , Relação Dose-Resposta a Droga , Feminino , Coração/efeitos dos fármacos , Interferon gama/análise , Interleucina-10/análise , Pulmão/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Masculino , Ratos , Ratos WistarRESUMO
In many countries the process of toxicity testing of environmental chemicals is ruled by a framework of OECD guidelines. The present paper will give an overview over the relevant OECD guidelines and guidance documents and mainly focus on methodological issues related to the prenatal toxicity testing guideline. Relevant guideline text will be provided, and practical recommendations will be given both for critical issues of experimental methodology and data interpretation.
Assuntos
Avaliação Pré-Clínica de Medicamentos/normas , Guias como Assunto , Agências Internacionais/normas , Praguicidas/toxicidade , Testes de Toxicidade/normas , Experimentação Animal/normas , Animais , HumanosRESUMO
This article summarizes the 7th Workshop on the Terminology in Developmental Toxicology held in Berlin, May 4-6, 2011. The series of Berlin Workshops has been mainly concerned with the harmonization of terminology and classification of fetal anomalies in developmental toxicity studies. The main topics of the 7th Workshop were knowledge on the fate of anomalies after birth, use of Version 2 terminology for maternal-fetal observations and non-routinely used species, reclassification of "grey zone" anomalies and categorization of fetal observations for human health risk assessment. The paucity of data on health consequences of the postnatal permanence of fetal anomalies is relevant and further studies are needed. The Version 2 terminology is an important step forward and the terms listed in this glossary are considered also to be appropriate for most observations in non-routinely used species. Continuation of the Berlin Workshops was recommended. Topics suggested for the next Workshop were grouping of fetal observations for reporting and statistical analysis.
Assuntos
Anormalidades Induzidas por Medicamentos/classificação , Feto/anormalidades , Terminologia como Assunto , Animais , Humanos , Medição de RiscoRESUMO
The former Soviet Union (USSR) and the USA were the first countries to introduce standards limiting exposure to radiofrequency (RF) fields. However, the exposure limits in the USSR standards were always much lower than those in the USA and other countries. The objective of this article is to provide a history of the development of the Soviet and Russian RF standards. In addition, we summarize the scientific evidence used to develop the original USSR RF and subsequent Russian public health standards, as well as the mobile telecommunications standard published in 2003, but we do not critique them. We also describe the protective approaches used by the Soviet and Russian scientists for setting their limits. A translation of the papers of the key studies used to develop their standards is available in the online version of this publication.
Assuntos
Saúde Pública/normas , Ondas de Rádio , Radiobiologia , Animais , Telefone Celular/normas , Humanos , Ondas de Rádio/efeitos adversos , Padrões de Referência , Federação RussaRESUMO
Results of key Soviet-era studies dealing with effects on the immune system and teratological consequences in rats exposed to radiofrequency (RF) fields serve, in part, as a basis for setting exposure limits in the USSR and the current RF standards in Russia. The World Health Organization's (WHO) International EMF Project considered these Soviet results important enough that they should be confirmed using more modern methods. Since the Soviet papers did not contain comprehensive details on how the results were obtained, Professor Yuri Grigoriev worked with Dr. Bernard Veyret to agree on the final study protocol and to conduct separate studies in Moscow and Bordeaux under the same protocol. The International Oversight Committee (IOC) provided oversight on the conduct of the studies and was the firewall committee that dealt with the sponsors and researchers. This paper gives the IOC comments and conclusions on the differing results between the two studies.
Assuntos
Anormalidades Congênitas/etiologia , Sistema Imunitário/efeitos da radiação , Internacionalidade , Lesões Experimentais por Radiação/etiologia , Ondas de Rádio/efeitos adversos , Animais , Testes de Fixação de Complemento , Ensaio de Imunoadsorção Enzimática , Feminino , Agências Internacionais , Ratos , Ratos Wistar , U.R.S.S. , Estudos de Validação como AssuntoRESUMO
In the context of pharmaceutical development today, studies for pediatric drug approval are requested more and more often by the regulatory authorities. The developing lung represents a potential target in juvenile toxicity studies. Due to physiological differences in prenatal and postnatal development between humans and standard animal models, experimental methods have to be modified to assess pulmonary function, and basic data on respiratory parameters need to be provided. Daily nose-only inhalation exposure from postnatal days 4 to 21 using a model substance (verapamil HCl) and plethysmographic measurements between postnatal days 2 and 50 were performed noninvasively in conscious juvenile Wistar (WU) rats. The methods proved to be feasible and did not interfere with normal growth and development of the animals. Both techniques therefore permit new insights to support human neonatal risk assessment and therefore these animal models are suitable for regulatory studies.
Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Pulmão/efeitos dos fármacos , Preparações Farmacêuticas , Administração por Inalação , Envelhecimento/efeitos dos fármacos , Animais , Animais Recém-Nascidos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Masculino , Preparações Farmacêuticas/administração & dosagem , Preparações Farmacêuticas/sangue , Pletismografia Total , Ratos , Ratos Wistar , Verapamil/administração & dosagem , Verapamil/efeitos adversos , Verapamil/sangueRESUMO
This update (Version 2) of the Terminology of Developmental Abnormalities in Common Laboratory Mammals (Version 1) incorporates improvements and enhancements to both content and organization of the terminology to enable greater flexibility in its application, while maintaining a consistent approach to the description of findings. The revisions are the result of an international collaboration among interested organizations, advised by individual experts and the outcomes of several workshops. The terminology remains organized into tables under the broad categories of external, visceral, and skeletal observations, following the manner in which data are typically collected and recorded in developmental toxicity studies. This arrangement of the tables, as well as other information provided in appendices, is intended to facilitate the process of specimen evaluation at the laboratory bench level. Only the commonly used laboratory mammals (i.e. rats, mice, rabbits) are addressed in the current terminology tables. The inclusion of other species that are used in developmental toxicity testing, such as primates, is considered outside the scope of the present update. Similarly, categorization of findings as, for example, 'malformation' or 'variation' remains unaddressed, in accordance with the overall principle that the focus of this document is descriptive terminology and not diagnosis or interpretation. The skeletal terms have been augmented to accommodate cartilage findings.
Assuntos
Animais de Laboratório/anormalidades , Terminologia como Assunto , Animais , MamíferosRESUMO
Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the International Conference on Harmonization (ICH) S5(R2) document (available at http://www.ich.org). The studies that assess developmental hazard are generally conducted in rodents and rabbits. Based on the authors' collective experience, adequate designs (including range-finding studies) and the presentation of data for these studies are described in detail. In addition, the suggested initiation and then total duration of these studies in relation to clinical studies that enroll women of childbearing potential are described. Optional parameters that may be included in the studies are discussed, as are study designs that combine assessments of fertility and developmental toxicity. New methods that may replace or enhance current procedures are outlined. The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies.
Assuntos
Anormalidades Induzidas por Medicamentos , Avaliação Pré-Clínica de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Desenvolvimento Embrionário/efeitos dos fármacos , Desenvolvimento Fetal/efeitos dos fármacos , Testes de Toxicidade/métodos , Animais , Animais Endogâmicos , Feminino , Agências Internacionais , Cooperação Internacional , Masculino , Exposição Materna , Camundongos , Coelhos , Ratos , Projetos de PesquisaRESUMO
Assessment of potential developmental and reproductive toxicity of human pharmaceuticals is currently guided by the ICH S5(R2) document. The studies that assess the hazard of both pre- and postnatal exposure are predominantly conducted in rodents (rat and mouse). Utilizing the collective experience of the authors, acceptable designs for both the range-finding and definitive studies are presented with detailed descriptions for the presentation of data. In addition, the suggested initiation and then total duration of these studies in relation to clinical studies are described. Optional parameters that may be included in the studies, as well as possible combination with other study designs are discussed. The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Desenvolvimento Embrionário/efeitos dos fármacos , Desenvolvimento Fetal/efeitos dos fármacos , Crescimento e Desenvolvimento/efeitos dos fármacos , Testes de Toxicidade/métodos , Animais , Relação Dose-Resposta a Droga , Agências Internacionais , Cooperação Internacional , Legislação de Medicamentos , Camundongos , Preparações Farmacêuticas/classificação , Ratos , Projetos de Pesquisa , Medição de RiscoRESUMO
The objective of juvenile animal toxicity studies of pharmaceuticals is to obtain safety data, including information on the potential for adverse effects on postnatal growth and development. Studies in juvenile animals may assist in identifying postnatal developmental toxicities or other adverse effects that are not adequately assessed in the routine toxicity evaluations and that cannot be safely or adequately measured in pediatric clinical trials. Unlike the traditional reproductive and developmental toxicology studies that have been discussed in the accompanying reports, the design requirements for toxicity studies in juvenile animals are not explicitly defined in regulatory guidance. However, studies in juvenile animals can be useful in providing safety information necessary to enable pediatric clinical trials in pediatric patients or when there are special concerns for toxicities that cannot be safely or adequately measured in clinical trials. These juvenile animal toxicity studies are designed on a case-by-case basis. General design considerations and examples of study designs for assessment of juvenile animal toxicity are discussed.
Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Crescimento e Desenvolvimento/efeitos dos fármacos , Pediatria , Projetos de Pesquisa , Testes de Toxicidade/métodos , Animais , Animais de Laboratório , Animais Recém-Nascidos , Feminino , Masculino , Preparações Farmacêuticas/classificação , Ratos , Ratos EndogâmicosRESUMO
This update (version 2) of the Terminology of developmental abnormalities in common laboratory mammals (version 1) by Wise et al. [Wise LD, Beck SL, Beltrame D, Beyer BK, Chahoud I, Clark RL, Clark R, Druga AM, Fueston MH, Guittin P, Henwood SM, Kimmel CA, Lindstrom P, Palmer AK, Petrere JA, Solomon HM, Yasuda M, York RG. Terminology of developmental abnormalities in common laboratory mammals (version 1). Teratology 1997;55:249-92] incorporates improvements and enhancements to both content and organization of the terminology, to enable greater flexibility in its application, while maintaining a consistent approach to the description of findings. The revisions are the result of an international collaboration among interested organizations, advised by individual experts and the outcomes of several workshops. The terminology remains organized into tables under the broad categories of external, visceral, and skeletal observations, following the manner in which data are typically collected and recorded in developmental toxicity studies. This arrangement of the tables, as well as other information provided in appendices, is intended to facilitate the process of specimen evaluation at the laboratory bench level. Only the commonly used laboratory mammals (i.e., rats, mice, rabbits) are addressed in the current terminology tables. The inclusion of other species that are used in developmental toxicity testing, such as primates, is considered outside the scope of the present update. Similarly, categorization of findings as, for example, "malformation" or "variation" remains unaddressed, in accordance with the overall principle that the focus of this document is descriptive terminology and not diagnosis/interpretation. The skeletal terms have been augmented to accommodate cartilage findings.
Assuntos
Animais de Laboratório/anormalidades , Terminologia como Assunto , Animais , MamíferosRESUMO
This update (Version 2) of the Terminology of Developmental Abnormalities in Common Laboratory Mammals (Version 1) by Wise et al. (1997) incorporates improvements and enhancements to both content and organization of the terminology, to enable greater flexibility in its application, while maintaining a consistent approach to the description of findings. The revisions are the result of an international collaboration among interested organizations, advised by individual experts and the outcomes of several workshops. The terminology remains organized into tables under the broad categories of external, visceral, and skeletal observations, following the manner in which data are typically collected and recorded in developmental toxicity studies. This arrangement of the tables, as well as other information provided in appendices, is intended to facilitate the process of specimen evaluation at the laboratory bench level. Only the commonly used laboratory mammals (i.e., rats, mice, rabbits) are addressed in the current terminology tables. The inclusion of other species that are used in developmental toxicity testing, such as primates, is considered outside the scope of the present update. Similarly, categorization of findings as, for example, "malformation" or "variation" remains unaddressed, in accordance with the overall principle that the focus of this document is descriptive terminology and not diagnosis/interpretation. The skeletal terms have been augmented to accommodate cartilage findings.